Cuộc họp báo cáo kết quả kinh doanh Quý 3/2026 của Pulmonx (LUNG): Doanh thu tăng trưởng trở lại
Doanh thu quý 3 năm 2026 của Pulmonx tăng 6% lên 22,8 triệu USD khi mức lỗ EBITDA đã điều chỉnh thu hẹp gần 60%. Ban lãnh đạo tái khẳng định dự báo ở mức 90 triệu - 92 triệu USD.
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.